Boundless Bio Inc BOLD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.41
- Day Range
- $1.40–1.45
- 52-Week Range
- $0.96–1.68
- Bid/Ask
- $1.39 / $1.42
- Shares Outstanding
- 22.46M
- Market Cap
- $31.45M
- Volume/Avg
- 64,978 / 213,284
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.boundlessbio.com
Valuation
|
Metric
|
BOLD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BOLD
|
|---|---|
Quick Ratio | 9.69 |
Current Ratio | 9.87 |
Interest Coverage | — |
Quick Ratio
BOLD
Profitability
|
Metric
|
BOLD
|
|---|---|
Return on Assets (Normalized) | −30.03% |
Return on Equity (Normalized) | −45.35% |
Return on Invested Capital (Normalized) | −34.38% |
Return on Assets
BOLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Qrpkvdpl | Pdjgjl | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zzsdplfr | Pgwldf | $64B | |||
| argenx SE ADR
ARGX
| Vrdnxncx | Ykxj | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rmphzmh | Xryjwzt | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Vfvjwkhkgc | Wwwzv | $24B | |||
| BioNTech SE ADR
BNTX
| Mkhhktl | Bbvm | $23B | |||
| Incyte Corp
INCY
| Mvlvdkc | Gck | $22B | |||
| Moderna Inc
MRNA
| Tldrgsk | Tmy | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Bngxlyxmw | Gsh | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Ybjrzksq | Dws | $13B |
United States